InflaRx to Report First Quarter 2025 Results on May 7, 2025

Rhea-AI Summary

InflaRx, a pioneering biopharmaceutical company listed on Nasdaq (IFRX), has announced it will release its first quarter 2025 financial and operating results on May 7, 2025, before market opening. No earnings call is scheduled.

The company specializes in developing anti-inflammatory therapeutics by targeting the complement system, specifically the C5a and C5aR pathways. Their flagship product, vilobelimab, is an intravenous first-in-class anti-C5a antibody that has shown promising clinical results across multiple indications. Additionally, they are developing INF904, an oral C5a receptor inhibitor.

Founded in 2007, InflaRx maintains offices in Jena and Munich, Germany, and Ann Arbor, Michigan, USA. The company operates through two wholly owned subsidiaries: InflaRx GmbH in Germany and InflaRx Pharmaceuticals in the USA.

Positive

• Development of two complementary drug candidates: vilobelimab (intravenous) and INF904 (oral)
• Established international presence with offices in Germany and USA
• Proprietary anti-C5a and anti-C5aR technology platform
• Multiple clinical studies showing disease-modifying activity for vilobelimab

Negative

• No earnings call scheduled, limiting investor interaction
• Forward-looking statements indicate significant risks and uncertainties
• Multiple clinical programs may increase cash burn rate

JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned.

About InflaRx

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.

InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

When will InflaRx (IFRX) release Q1 2025 financial results?

InflaRx (IFRX) will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No earnings conference call is scheduled.

What are InflaRx's main drug candidates and therapeutic focus?

InflaRx's lead product is vilobelimab, an intravenous anti-C5a monoclonal antibody, and they're developing INF904, an oral C5a receptor inhibitor. They focus on anti-inflammatory therapeutics targeting the complement system, specifically C5a and C5aR.

Where is InflaRx (IFRX) located and operating?

InflaRx has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, Michigan, USA. The company was founded in 2007.

How does InflaRx's (IFRX) technology platform work?

InflaRx uses proprietary anti-C5a and anti-C5aR technologies to develop highly specific inhibitors of C5a, a powerful inflammatory mediator, and its receptor C5aR for treating various inflammatory diseases.

What is vilobelimab and how effective is it?

Vilobelimab is InflaRx's first-in-class, intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a. According to the company, it has demonstrated disease-modifying clinical activity and tolerability across multiple clinical studies in different indications.